A Phase 3, 182-week, Open-Label, Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (snOH) in Subjects with Primary Autonomic Failure

Project: Research

Project Details

StatusActive
Effective start/end date25/05/2124/05/26

Keywords

  • phase 3 study
  • treatment safety
  • treatment efficacy
  • neurodegenerative disorders